Introduction
It is well-known that a controlled drug release can be realized by physical and chemical mechanisms. The most investigated and used mechanism for medical applications is the diffusion-controlled drug release that is based on the diffusion of drug molecules through a membrane or matrix, mostly of polymeric nature. Due to their different chemical structures polymers allow for a wide range of control over the drug release characteristics. In this context, it is well-known that more hydrophilic polymeric matrices facilitate a higher water uptake and hence realize a faster drug release than hydrophobic polymers. Additionally, the use of biodegradable polymers is favoured, because they degrade once their function as coating matrix and/or drug depot is fulfilled. Chemically controlled LDD systems offer another strategy for drug release. In these systems, drug release is achieved generally by cleavage of chemically bound drugs or biomolecules. Systems providing controlled, local release of active substances are of interest in different medical applications. For instance, drug-eluting stents (DES) have impressively demonstrated their capability of reducing in-stent restenosis. Since the secondary cataract formation or glaucoma progression was prevented by the ocular application of pharmacological agents, there are further examples in ophthalmology which demonstrate the growing demand for LDD systems. Therefore, we developed injectable LDD systems on the basis of biodegradable polymers which realize different drug release profiles according to the clinical requirements. For the secondary cataract prevention a fast delivery of antiproliferative drugs within a time frame of 5 min is required due to clinical procedures for lens replacement. With the purpose to realize a safe drug application and a fast drug release we embedded 10 µM of antiproliferative model drugs, such as methotrexate (MTX) or/and actinomycin D (AM), in 1% (w) hyaluronic acid sodium salt (HA) gel as hydrophilic drug carrier and studied their actions in detail in vitro and in vivo [1] . For subconjunctival glaucoma treatment and a sustained local drug release we developed a two-component LDD system consisting of HA and the more hydrophobic isocyanate functionalized 1,2-ethylene glycol bis(dilactic acid) (ELA-NCO) from own previous research [2] and investigated its in vitro biocompatibility and drug release behaviour depending on the ratio of both components. This novel biodegradable LDD system is characterized by the reaction of both components under in situ polyurethane formation. The scheme of reaction of HA with ELA-NCO is shown in Figure 1 . As model drugs for glaucoma treatment timolol maleate (TM) and latanoprost (LA) were used. 
Materials and Methods
Materials: TM and all other chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany). LA was used from Hangzhou Dayangchem Co. Ltd. (China). HA (from streptococcus equi, M w =1,500,000 Da) were obtained from Fluka (Taufkirchen, Germany). 1,2-ethylene glycol bis(dilactic acid) (ELA, with n=1) was synthesized and endowed with terminal reactive isocyanate groups by reaction with hexamethylene diisocyanate according to [2] . To reduce its viscosity and enhance its handling ELA-NCO was diluted in absolute dimethyl sulfoxide (DMSO, 15% w). For drug incorporation 250 mg TM were mixed with 9.5 g water before 250 mg HA were added. After stirring overnight a TM containing colourless HA gel was obtained. Due to its low solubility LA was handled as suspension of 250 mg LA in 9.5 g water before under strong stirring 250 mg HA were added again. The components HA+TM or LA/ELA-NCO were applied with a double chamber syringe adapted to a mixing extruder (Sulzer Mixpac AG, Rotkreuz, Switzerland) giving the different ratios of 1/1, 1/4 and 1/10 (v/v). In vitro drug release: The time course of TM and LA release was determined at 37 °C from freshly polymerized samples with masses of approx. 150-200 mg. For HPLC measurements the samples were injected in glass vials and covered immediately with 1 ml of 0.9% NaCl solution. At different time points 20 µL of the test solutions were injected into an Eurospher column 100-5, C18, 120 x 4 mm ID (Wissenschaftlicher Gerätebau Dr.-Ing. Herbert Knauer GmbH, Berlin, Germany). In vitro biocompatibility: Human Tenon fibroblasts (hTF) were cultured under standard conditions at 37 °C, 5% CO 2 and relative humidity of 95%. DMEM with Lglutamine (Sigma-Aldrich), 2.2 g/l NaHCO 3 , 10% FCS, 5 µg/ml gentamicin (PromoCell, Heidelberg, Germany), 2.5 µg/ml amphotericin B (PAA, Cölbe, Germany) was used and adjusted to pH 7.4. For eluate preparation polymerized HA/ELA-NCO samples were incubated with DMEM (0.2 g sample/ml) and eluted for 24 h at 37 °C. 24 h after seeding (2.000 cells/200 µl DMEM) hTF were incubated with serial dilutions (100-3.125%) of a HA/ELA-NCO eluate and in parallel with equivalent dilutions of DMSO for 48 h. As negative control (NC) hTF were incubated with DMEM only. Then eluate dilutions or DMEM were removed and replaced by a 1:10 dilution of CellQuantiBlue™ Cell Viability Assay reagent (BioAssay Systems, Hayward, USA) in DMEM for 2 h. Fluorescence was measured (544 nm excitation, 590 nm emission).
Results
The in vitro biocompatibility study using hTF demonstrated that the undiluted eluate (100%) of ELA-NCO resulted in a decrease of relative cell viability of up to 65%, whereas the 100%-eluate of the polymerized HA/ELA-NCO (1/1 v/v) samples caused a relative cell viability of approx. 77% (Fig. 2) . Analogous dilutions of DMSO corresponding to its content in the polymer samples caused a similar decrease of relative cell viability (Fig. 2) . The performed in vitro drug release studies confirmed the assumption that the drug is released faster if the content of the hydrophilic HA is increased in comparison to ELA-NCO (Fig. 3) . Furthermore, we could determine that LDD systems using the water soluble drug TM in combination with a high HA content cause a drug release profile with a high drug release rate in the initial phase and a sustained drug release within the investigated period of 1000 h (Fig. 3) . In contrast, LDD systems using LA have the potential for a sustained drug release, because the drug release is more influenced by LA solubility than by the composition of the polymeric LDD matrix. 
Discussion
It can be stated that the presented results are promising for the development of a specially tailored injectable LDD system intended for subconjunctival glaucoma treatment. However, to avoid drug-induced toxic side effects the burst release in the initial phase should be minimized by use of hydrophobic/lipophilic drugs or by the purposeful control of the mixing ratio of the two polymeric components. It was also observed that the decreased biocompatibility of the LDD system is caused, at least in part by DMSO. Therefore, in future investigations DMSO will be replaced by less toxic organic solvents.
